Premium
PET‐DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)
Author(s) -
Balzarotti M.,
Ricardi U.,
Spina M.,
Monagheddu C.,
Tucci A.,
Cavallo F.,
Zanni M.,
Arcari A.,
Rusconi C.,
Sartori R.,
Merli F.,
Re F.,
Vitolo U.,
Dessi D.,
Melis L.,
Gaidano G.,
Chiti A.,
Deidda M.,
Santoro A.,
Ciccone G.,
Chauvie S.,
Cabras M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.62_2630
Subject(s) - medicine , diffuse large b cell lymphoma , nuclear medicine , clinical endpoint , rituximab , hazard ratio , phases of clinical research , radiation therapy , lymphoma , clinical trial , confidence interval